Medicamen Biotech Ltd

₹ 296 -1.76%

02 Mar 4:01 p.m.

medicamen.com BSE: 531146 NSE: MEDICAMEQ

About

Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations^[1]

Key Points

Business Overview:^[1]^[2]^[3]
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.

Website BSE NSE

Market Cap ₹ 401 Cr.
Current Price ₹ 296
High / Low ₹ 545 / 277
Stock P/E 45.4
Book Value ₹ 201
Dividend Yield 0.34 %
ROCE 6.77 %
ROE 4.43 %
Face Value ₹ 10.0

Add ratio to table

Edit ratios

Pros

Cons

The company has delivered a poor sales growth of 5.24% over past five years.
Company has a low return on equity of 6.45% over last 3 years.
Earnings include an other income of Rs.6.59 Cr.
Dividend payout has been low at 10.5% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
	34.12	37.15	40.50	42.67	44.20	45.01	41.48	42.84	41.14	26.00	38.45	42.23	43.49
	28.26	30.38	33.09	36.51	38.61	38.18	36.62	36.29	34.90	27.10	34.42	37.18	38.41
Operating Profit	5.86	6.77	7.41	6.16	5.59	6.83	4.86	6.55	6.24	-1.10	4.03	5.05	5.08
OPM %	17.17%	18.22%	18.30%	14.44%	12.65%	15.17%	11.72%	15.29%	15.17%	-4.23%	10.48%	11.96%	11.68%
	0.63	0.35	0.38	0.55	0.83	0.54	0.58	0.29	0.14	5.22	0.47	0.37	0.53
Interest	0.68	0.86	0.96	0.91	0.65	1.87	0.68	1.01	0.73	0.62	0.56	0.84	0.78
Depreciation	1.60	1.61	1.68	1.80	1.76	1.77	1.74	2.57	2.17	0.48	1.77	1.81	1.75
Profit before tax	4.21	4.65	5.15	4.00	4.01	3.73	3.02	3.26	3.48	3.02	2.17	2.77	3.08
Tax %	10.69%	13.12%	14.37%	24.75%	31.17%	16.62%	25.17%	30.06%	27.59%	20.86%	24.42%	20.22%	15.58%
	3.76	4.05	4.42	3.01	2.77	3.10	2.26	2.27	2.52	2.40	1.64	2.21	2.59
EPS in Rs	2.97	3.20	3.49	2.38	2.19	2.44	1.78	1.79	1.98	1.89	1.21	1.63	1.91
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
	73	78	67	82	112	123	117	110	115	138	172	151	150
	68	73	62	71	95	105	99	90	91	113	145	134	137
Operating Profit	5	5	6	12	17	17	18	20	24	25	27	17	13
OPM %	7%	6%	8%	14%	15%	14%	15%	18%	21%	18%	16%	11%	9%
	1	1	1	0	2	4	2	1	2	2	2	6	7
Interest	4	4	4	4	3	1	1	2	2	3	6	4	3
Depreciation	2	2	2	2	2	2	2	3	6	6	7	7	6
Profit before tax	0	0	1	6	14	18	17	17	18	17	17	13	11
Tax %	44%	-267%	32%	19%	27%	31%	26%	25%	18%	13%	21%	26%
	0	0	0	5	10	12	12	12	15	15	13	9	9
EPS in Rs	0.10	0.46	0.48	4.91	8.89	10.28	10.04	10.22	12.20	11.86	10.46	7.43	6.64
Dividend Payout %	0%	0%	0%	0%	12%	10%	5%	10%	8%	8%	10%	13%

Compounded Sales Growth
10 Years:	7%
5 Years:	5%
3 Years:	9%
TTM:	-12%

Compounded Profit Growth
10 Years:	36%
5 Years:	-5%
3 Years:	-14%
TTM:	-13%

Stock Price CAGR
10 Years:	20%
5 Years:	-14%
3 Years:	-24%
1 Year:	-42%

Return on Equity
10 Years:	9%
5 Years:	8%
3 Years:	6%
Last Year:	4%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	9	10	10	11	12	12	12	12	12	13	13	13	14
Reserves	8	8	8	16	63	75	110	122	136	181	196	205	258
	15	21	19	18	14	12	11	19	26	26	30	27	31
	33	31	23	29	28	38	43	39	52	57	55	48	48
Total Liabilities	65	69	60	73	118	137	176	192	226	277	294	293	351
	22	20	19	19	25	24	34	90	92	92	91	86	85
CWIP	1	0	0	0	0	15	40	0	0	0	0	0	0
Investments	0	0	0	0	0	0	2	2	2	4	8	8	8
	42	49	41	54	92	97	100	101	131	180	195	199	258
Total Assets	65	69	60	73	118	137	176	192	226	277	294	293	351

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	5	-3	6	4	-5	4	12	13	5	-4	-0	-3
	-1	0	-1	-2	-8	-15	-39	-18	-8	-8	-9	-2
	-4	3	-5	-1	33	-4	21	6	4	28	3	-7
Net Cash Flow	1	-0	0	0	20	-14	-6	1	1	17	-6	-11

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	102	124	87	114	126	129	137	165	193	159	102	141
Inventory Days	95	95	95	102	77	67	85	28	188	230	237	274
Days Payable	209	187	160	165	118	134	160	161	291	232	152	182
Cash Conversion Cycle	-13	32	22	51	85	62	62	32	91	157	188	234
Working Capital Days	-32	7	3	34	89	116	139	130	146	151	117	186
ROCE %	13%	12%	12%	24%	25%	20%	15%	13%	12%	11%	10%	7%

Shareholding Pattern

Numbers in percentages

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
	43.21%	43.21%	43.21%	43.21%	43.21%	42.99%	42.99%	42.99%	43.16%	40.46%	40.46%	40.46%
	0.19%	0.16%	0.22%	0.22%	0.12%	0.06%	0.06%	0.06%	0.12%	0.00%	0.05%	0.02%
	0.20%	0.20%	0.20%	0.67%	0.99%	1.17%	1.17%	0.87%	0.69%	0.64%	0.59%	0.44%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%	0.06%	0.05%	0.05%	0.05%
	56.40%	56.44%	56.38%	55.90%	55.69%	55.78%	55.79%	56.04%	55.99%	58.83%	58.84%	59.02%
No. of Shareholders	8,233	8,272	9,419	10,252	10,639	10,652	10,792	10,576	10,435	10,808	11,177	10,967

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Dec 2025
	45.51%	45.37%	44.53%	44.77%	44.83%	43.60%	43.21%	43.21%	43.16%	40.46%
	0.14%	0.49%	0.49%	0.47%	0.44%	0.40%	0.19%	0.12%	0.12%	0.02%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.20%	0.99%	0.69%	0.44%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.06%	0.05%
	54.35%	54.14%	54.99%	54.76%	54.73%	56.01%	56.40%	55.69%	55.99%	59.02%
No. of Shareholders	4,095	4,802	4,684	4,542	4,965	9,300	8,233	10,639	10,435	10,967

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Nov 2024

Transcript

AI Summary
PPT
Dec 2021

Transcript

AI Summary
PPT
Nov 2020

Transcript

AI Summary
PPT
Aug 2020

Transcript

AI Summary
PPT
Jun 2020

Transcript

AI Summary
PPT